- Conditions
- End Stage Renal Failure on Dialysis
- Interventions
- Argyle Safety Fistula Cannula with Anti-Reflux Valve
- Device
- Lead sponsor
- Mozarc Medical US LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 3
- States / cities
- Hartford, Connecticut • Columbus, Georgia • Norfolk, Virginia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 109
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Chronic Kidney Disease, End Stage Renal Disease, Hemodialysis, Peritoneal Dialysis
- Interventions
- Comprehensive Pre-ESRD Patient Education (CPE), Provision of the freely available resources for Kidney Disease Education
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 656 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Chronic Kidney Disease, Chronic Renal Disease
- Interventions
- Polyflux HD-C4 Big, HD-C4 Small, Optiflux 160NR, Optiflux 200NR
- Device
- Lead sponsor
- Vantive Health LLC
- Industry
- Eligibility
- 19 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Kidney Failure, Chronic, Renal Dialysis
- Interventions
- somatropin
- Drug
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 1 Month to 16 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Kansas City, Missouri • The Bronx, New York + 1 more
- Conditions
- Anemia
- Interventions
- Peginesatide
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Sacramento, California • San Diego, California + 7 more
- Conditions
- End Stage Renal Disease (ESRD)
- Interventions
- AGE
- Other
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Renal Insufficiency, Chronic, Kidney Failure, Chronic
- Interventions
- Vitamin D
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Chronic Renal Failure, Chronic Kidney Disease, Anemia
- Interventions
- peginesatide, Darbepoetin alfa
- Drug
- Lead sponsor
- Affymax
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 490 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 68
- States / cities
- Montgomery, Alabama • Tempe, Arizona • Hot Springs, Arkansas + 62 more
- Conditions
- End Stage Renal Failure on Dialysis
- Interventions
- Hemodialysis, Patiromer Oral Product
- Other · Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Hyperparathyroidism, Secondary, Kidney Failure, Chronic
- Interventions
- doxercalciferol
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Hypoalbuminemia, Protein-energy Malnutrition, Inflammation, Oxidative Stress, Chronic Kidney Disease (CKD) Hemodialysis
- Interventions
- pentoxiphylline, Nepro, anti-inflammatory module (similar to Oxepa), Placebo pill imitating pentoxiphylline, Placebo to imitate Nepro, Placebo to imitate anti-inflammatory module (similar to Oxepa)
- Drug · Dietary Supplement
- Lead sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 2
- States / cities
- Irvine, California • Torrance, California
- Conditions
- Accidental Falls, Fall Due to Loss of Equilibrium, High Risk of Falls Due to Mobility Limitation, Diabetes, Arthritis, Cancer, Peripheral Arterial Disease, Parkinson's Disease, End Stage Renal Failure on Dialysis
- Interventions
- MBB AFO, Control
- Device · Other
- Lead sponsor
- Bijan Najafi, PhD
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- End Stage Renal Disease, Kidney Failure, Renal Failure, Hyperphosphatemia, ESRD
- Interventions
- ferric citrate
- Drug
- Lead sponsor
- Keryx Biopharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 33
- States / cities
- Los Angeles, California • Aurora, Colorado • Westminster, Colorado + 26 more
- Conditions
- Chronic Kidney Disease, Chronic Renal Disease
- Interventions
- Dialysis Flow Rate Start 600mL/min, Dialysis Flow Rate Start 800mL/min
- Other
- Lead sponsor
- Vantive Health LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 3
- States / cities
- Sacramento, California • Louisville, Kentucky • Nashville, Tennessee
- Conditions
- End Stage Renal Disease
- Interventions
- Triferic
- Drug
- Lead sponsor
- Rockwell Medical Technologies, Inc.
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Loma Linda, California • Stanford, California + 6 more
- Conditions
- End Stage Renal Failure on Dialysis, Frail Elderly Syndrome
- Interventions
- Exercise Plan using resistance bands, Modified Fried Frailty Scale
- Other · Diagnostic Test
- Lead sponsor
- Satellite Healthcare
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Milpitas, California
- Conditions
- End Stage Renal Failure on Dialysis, Actual Impaired Fluid Volume, Kidney Failure
- Interventions
- dry weight adjustment
- Other
- Lead sponsor
- VA New York Harbor Healthcare System
- Federal
- Eligibility
- 21 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- End Stage Renal Disease, Depression
- Interventions
- Cognitive behavioral therapy
- Behavioral
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- End Stage Renal Disease (ESRD), End Stage Renal Disease on Dialysis, Acute Kidney Injury
- Interventions
- Tablo Hemodialysis System
- Device
- Lead sponsor
- Outset Medical
- Industry
- Eligibility
- Not listed
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- End Stage Renal Disease, Chronic Kidney Disease
- Interventions
- Cognitive Function Testing-10 Tests, Sleep Assessment Testing, Periodic Leg Movement Syndrome Assessment
- Other
- Lead sponsor
- Satellite Healthcare
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 2
- States / cities
- Mountain View, California
- Conditions
- Chronic Renal Failure, Chronic Kidney Disease, Anemia
- Interventions
- peginesatide, Epoetin Alfa
- Drug
- Lead sponsor
- Affymax
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 803 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 89
- States / cities
- Paragould, Arkansas • Fairfield, California • Granada Hills, California + 76 more
- Conditions
- End Stage Kidney Disease
- Interventions
- Website Intervention
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 2
- States / cities
- Davis, California • Chicago, Illinois
- Conditions
- Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis, End Stage Renal Disease on Dialysis
- Interventions
- AP306 75 mg BID, AP306 125 mg BID, AP306 150 mg BID, AP306 75 mg TID, AP306 100 mg TID, AP306 125 mg TID, Placebo
- Drug
- Lead sponsor
- R1 Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 24
- States / cities
- Huntsville, Alabama • Chula Vista, California • Los Angeles, California + 19 more
- Conditions
- Chronic Kidney Failure, End-stage Renal Disease, Disorders Associated With Peritoneal Dialysis
- Interventions
- lanthanum carbonate
- Drug
- Lead sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Other
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Torrance, California